• Publications
  • Influence
Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder: Results of a Pilot Study
Objective: To evaluate the effect of 32-mg/d naltrexone sustained release and 360-mg/d bupropion sustained release (NB32) in overweight and obese patients with major depressive disorder (MDD).Expand
Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers
Objective To compare the pharmacokinetics of the extended-release MMX® formulation of budesonide (Uceris®) with that of Entocort® EC, an extended (controlled ileal) release formulation of budesonide.Expand
Tu1252 Effect of Budesonide MMx 6 mg on the Hypothalamic-Pituitary-Adrenal (HPA) Axis in Patients With Ulcerative Colitis: Results From a Phase III, 12 Month Safety and Extended use Study
follow-up time from first biologic 4.5 years (IQR 1.4-7.6). 1751 IFX infusions were given, with increasing frequency over time reflecting the shift from episodic to maintenance therapy. InfusionExpand
P-148 Budesonide MMX Versus Placebo in Patients with Active, Mild-to-Moderate Ulcerative Colitis who Were 5-ASA Naïve or Previously Treated with 5-ASA
BACKGROUND: Current guidelines recommend patients with active, mild-to-moderate ulcerative colitis (UC) receive initial therapy with mesalamine (5-ASA), escalating to treatment with systemic steroidsExpand
P-144 Symptom Resolution and Clinical and Endoscopic Remission Both Resulted in Improved Quality of Life in Patients with Ulcerative Colitis
BACKGROUND: Ulcerative colitis (UC) is a chronic, idiopathic, relapsing and remitting inflammatory disease of the colon. Impaired quality of life is often a concern in patients with UC. From aExpand